| Assessment Status | NCPE Assessment Process complete |
| HTA ID | 22066 |
| Drug | Axicabtagene ciloleucel |
| Brand | Yescarta® |
| Indication | For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. |
| Assessment Process | |
| Rapid review commissioned | 27/09/2022 |
| Rapid review completed | 10/11/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axicabtagene ciloleucel compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 30/11/2022 |
| Pre-submission consultation with Applicant | 21/03/2023 |
| Full submission received from Applicant | 06/09/2023 |
| Preliminary review sent to Applicant | 01/03/2024 |
| NCPE assessment re-commenced | 28/03/2024 |
| Factual accuracy sent to Applicant | 31/07/2024 |
| NCPE assessment re-commenced | 08/08/2024 |
| NCPE assessment completed | 16/10/2024 |
| NCPE assessment outcome | The NCPE recommends that axicabtagene ciloleucel (Yescarta ®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
